Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 in Patient With Hypertension
NCT ID: NCT01413048
Last Updated: 2011-08-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
260 participants
INTERVENTIONAL
2011-01-31
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension
NCT04686643
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy
NCT05526703
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
NCT05503953
Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension
NCT01756430
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy
NCT05931224
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AGSCT101
AGSCT101 12.5mg
Tablet, q.d.
Carvedilol
Carvedilol 25mg
Tablet, q.d.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Carvedilol 25mg
Tablet, q.d.
AGSCT101 12.5mg
Tablet, q.d.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Mild to moderate essential hypertension: sDBP 90 \~ 109, sSBP 140 \~ 179
* Subjects who agree to participate in this sudy and give written informed consent
* Subjects considered to understand the study, be cooperative, and able to be followed-up until the end of the study
Exclusion Criteria
* Patients with postural hypotension
* Patients with severe renal(Creatinine more 1.5mg/dl), gastrointestinal, hematological or hepatic(AST, ALT more 3 times more than upper limit of normal)disease
* Female of childbearing potential who does not undergo hysterectomy or is not post-menopausal
* Patients judged to have a history of alcohol or drug abuse by the investigator
* Patients with a history of myocardial infarction, severe coronary artery disease or clinically significant heart failure or valvular defect in last 6 months
* Patients with uncontrolled diabetes mellitus
* Patients participated other clinical trial 12 weeks before Screening Patients judged to be inappropriate for this study by the investigator with other reasons
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ahn-Gook Pharmaceuticals Co.,Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Project Planning and Development Team
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ki-Bae Seung, Professor
Role: PRINCIPAL_INVESTIGATOR
The Catholic University of Korea-St. Mary's Hospital
Hun-Sik Park, Professor
Role: PRINCIPAL_INVESTIGATOR
Kyungpook National University Hospital
Chang-Gyu Park, Professor
Role: PRINCIPAL_INVESTIGATOR
Korea University Guro Hospital
Moo-Yong Rhee, Professor
Role: PRINCIPAL_INVESTIGATOR
Dongguk University Medical Center
Dong-Ju Choi, Professor
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Bundang Hospital
Seung-Jea Tahk, Professor
Role: PRINCIPAL_INVESTIGATOR
Ajou University School of Medicine
Jung-Han Yoon, Professor
Role: PRINCIPAL_INVESTIGATOR
Wonju Christian Hospital
Sung-Ha Park, Professor
Role: PRINCIPAL_INVESTIGATOR
Severance Hospital
Myung-Ho Jeong, Professor
Role: PRINCIPAL_INVESTIGATOR
Chonnam National University Hospital
Sang-Wook Kim, Professor
Role: PRINCIPAL_INVESTIGATOR
Chung-Ang University Hosptial, Chung-Ang University College of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Catholic University of Korea-St. Mary's Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ki-bae Seung, Professor
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1001AGCVSP3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.